JUM GE Healthcare
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolevski, G.
Right arrow Articles by Petrova, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolevski, G.
Right arrow Articles by Petrova, V.
© 2007 by the American Institute of Ultrasound in Medicine
J Ultrasound Med 26:509-512 • 0278-4297

Case Series

Transcranial Sonography in the Evaluation of Parkinson Disease

Goran Kolevski, MD, Igor Petrov, MD and Vera Petrova, MD

Clinic of Neurology, Clinical Center-Skopje, Skopje, Macedonia.

Address correspondence to Goran Kolevski, MD, Ulica Rayko Zinzifov 52/1/5, 1000 Skopje, Macedonia. E-mail: gogomk{at}hotmail.com

Objective. With transcranial sonography (TS), it is possible to visualize hyperechoic signals in the sub-stantia nigra (SN) in patients with Parkinson disease (PD). Our objective was to correlate the level of echogenicity in the SN with clinical status in patients with PD. Methods. In our pilot study, using TS, we examined 15 patients with the confirmed presence of PD. Staging of the latest clinical status was evaluated according to the Hoehn and Yahr scale. According to TS, the level of echogenicity was graduated as hypoechogenicity, moderate hyperechogenicity, and severe hyperechogenicity. Results. Of the patients with severe hyperechogenicity (8 patients), 7 had Hoehn and Yahr stage III disease, and 1 had stage II disease. Of the patients with moderate hyperechogenicity (6 patients), 4 had stage II disease; 1 had stage III disease; and 1 had stage I disease. The patient with hypoechogenicity had stage I disease. Statistical analysis showed that there was a significant correlation between the level of echogenicity in the SN and the clinical stage (r = 0.7735; P = .0007). Conclusions. In our pilot study, although only a small number of patients were included, we confirmed the usefulness of TS in the evaluation of PD.

Key Words: hyperechogenicity • Parkinson disease • transcranial sonography

Abbreviations: PD, Parkinson disease • TS, transcranial sonography

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Institute of Ultrasound in Medicine.